Base de dados : MEDLINE
Pesquisa : C04.557.450.565.465.500 [Categoria DeCS]
Referências encontradas : 280 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 28 ir para página                         

  1 / 280 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776809
[Au] Autor:Maciejewski M; Debarre JM; Georgin-Lavialle S; Kettani S; Olschwang S; Guérin-Moreau M; Le Corre Y; Martin L
[Ad] Endereço:Service de dermatologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France.
[Ti] Título:[Metameric macular and papular skin mastocytosis].
[Ti] Título:Mastocytose cutanée maculopapuleuse métamérique..
[So] Source:Ann Dermatol Venereol;144(3):208-211, 2017 Mar.
[Is] ISSN:0151-9638
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:BACKGROUND: Mastocytosis is characterised by the presence of abnormal quantities of mastocytes in one or more organs. Although it occurs in systemic forms of mastocytosis, isolated skin involvement is the predominant presentation, particularly in children, in the form of more or less extensive though non-systematic lesions. Herein, we report a case of maculopapular cutaneous mastocytosis that is unusual in terms of its metameric topography. PATIENTS AND METHODS: A 16-year-old youth presented with an erythematous maculopapular rash of 18 months' duration and involving pruritic inflammatory episodes strictly localised in segment T8 to the left. The skin biopsy showed a significant increase in the number of dermal mastocytes (CD117+). No KIT mutations were found in the skin lesions nor in the unimpaired skin of the opposite side. Further investigations ruled out systemic mastocytis. DISCUSSION: Herein, we report a case of cutaneous mastocytosis that is unusual in terms of its metameric disposition. There have been only two previous reports of segmental cutaneous mastocytis. The two pathological hypotheses involved precessional dermatitis that renders the skin surface susceptible to homing, and somatic mosaicism (type 1) with local mastocyte proliferation.
[Mh] Termos MeSH primário: Mastócitos/patologia
Mastocitose Cutânea/patologia
[Mh] Termos MeSH secundário: Adolescente
Biópsia
Diagnóstico Diferencial
Seres Humanos
Masculino
Pele/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180126
[Lr] Data última revisão:
180126
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  2 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29049637
[Au] Autor:Maya Y; Takashima S; Ota M
[Ad] Endereço:Department of Dermatology, Chitose City Hospital, Chitose, Japan.
[Ti] Título:Multiple Hyperpigmented Macules in a Child.
[So] Source:JAMA;318(15):1493-1494, 2017 Oct 17.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Hiperpigmentação/diagnóstico
Mastocitose Cutânea/diagnóstico
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Hiperpigmentação/patologia
Lactente
Mastocitose Cutânea/patologia
[Pt] Tipo de publicação:CASE REPORTS
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171020
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.13861


  3 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28129097
[Au] Autor:Halsey CHC; Thamm DH; Weishaar KM; Burton JH; Charles JB; Gustafson DL; Avery AC; Ehrhart EJ
[Ad] Endereço:1 Cell and Molecular Biology, Colorado State University, Fort Collins, CO, USA.
[Ti] Título:Expression of Phosphorylated KIT in Canine Mast Cell Tumor.
[So] Source:Vet Pathol;54(3):387-394, 2017 May.
[Is] ISSN:1544-2217
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Canine cutaneous mast cell tumor (MCT) is the most common canine skin tumor and exhibits variable biologic behavior. Signaling through the KIT receptor tyrosine kinase promotes cellular proliferation and survival and has been shown to play a role in MCT progression. Despite investigations into numerous biomarkers and the proposal of several grading schemas, no single marker or grading system can accurately predict outcome in canine MCT. The first aim of this study was to develop an immunohistochemical assay to measure phosphorylated KIT (pKIT) to investigate its association with 2 commonly used grading systems and other established prognostic markers for canine MCT. Thirty-four archived MCTs were evaluated for expression of pKIT and Ki-67, KIT localization, mitotic count, mutations in exons 8 and 11 in c-kit, and grading by the Patnaik and 2-tier systems. Expression of pKIT was significantly ( P < .05) correlated with the 2-tier grading scheme and c-kit mutation. Correlation approached significance ( P = .06) with Mitotic Index (MI) and Ki-67. An additional aim was to determine whether pKIT labeling provides a pharmacodynamic marker for predicting response to the receptor tyrosine kinase inhibitor toceranib (TOC). MCTs from 4 of 7 patients demonstrated a partial response to TOC. pKIT expression was assessed by immunohistochemistry in biopsies obtained before and 6 hours after the patients were treated with TOC. Reduced pKIT expression after TOC treatment was demonstrated in 3 of the 4 patients with a partial response compared to 1 of the 3 nonresponders. Collectively, these results demonstrate that immunohistochemical detection of pKIT may be a clinically relevant assay to evaluate the activation status of the major oncogenic pathway in canine MCT.
[Mh] Termos MeSH primário: Doenças do Cão/patologia
Mastocitose Cutânea/veterinária
Proteínas Proto-Oncogênicas c-kit/metabolismo
[Mh] Termos MeSH secundário: Animais
Biomarcadores
Doenças do Cão/diagnóstico
Cães
Mastocitose Cutânea/diagnóstico
Mastocitose Cutânea/patologia
Fosforilação
Prognóstico
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170128
[St] Status:MEDLINE
[do] DOI:10.1177/0300985816688943


  4 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27981619
[Au] Autor:Piqueres-Zubiaurre T; Martínez de Lagrán Z; González-Pérez R; Urtaran-Ibarzabal A; Perez de Nanclares G
[Ad] Endereço:Service of Dermatology, OSI Araba University Hospital, Vitoria-Gasteiz, Alava, Spain.
[Ti] Título:Familial Progressive Hyperpigmentation, Cutaneous Mastocytosis, and Gastrointestinal Stromal Tumor as Clinical Manifestations of Mutations in the c-KIT Receptor Gene.
[So] Source:Pediatr Dermatol;34(1):84-89, 2017 Jan.
[Is] ISSN:1525-1470
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Familial progressive hyperpigmentation (FPH) is an autosomal dominant disorder characterized by the appearance of hyperpigmented patches on the skin from early infancy that increase in size and number with age. METHODS: We report the clinical and molecular studies of an 11-year-old boy who had areas of hyperpigmentation since birth that had spread across his body as irregular hyperpigmented macules and papules, and include relevant history in family members. RESULTS: Affected members of his family shared a mutation in the c-KIT gene. All had progressive hyperpigmentation, in some cases accompanied by gastrointestinal stromal tumors and mastocytoma. There have been few reports of familial progressive hyperpigmentation together with systemic manifestations. CONCLUSIONS: Molecular analysis of c-KIT should be considered in the presence of FPH with systemic involvement.
[Mh] Termos MeSH primário: Tumores do Estroma Gastrointestinal/genética
Hiperpigmentação/genética
Mastocitose Cutânea/genética
Proteínas Proto-Oncogênicas c-kit/genética
[Mh] Termos MeSH secundário: Criança
Seres Humanos
Lactente
Masculino
Mutação
Pele/patologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170427
[Lr] Data última revisão:
170427
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161217
[St] Status:MEDLINE
[do] DOI:10.1111/pde.13040


  5 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25643820
[Au] Autor:Smith J; Kiupel M; Farrelly J; Cohen R; Olmsted G; Kirpensteijn J; Brocks B; Post G
[Ad] Endereço:Department of Medical Oncology, Chicago Veterinary Cancer Center, Chicago, IL, USA.
[Ti] Título:Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone.
[So] Source:Vet Comp Oncol;15(1):36-45, 2017 Mar.
[Is] ISSN:1476-5829
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Grade II mast cell tumours (MCT) are tumours with variable biologic behaviour. Multiple factors have been associated with outcome, including proliferation markers. The purpose of this study was to determine if extent of surgical excision affects recurrence rate in dogs with grade II MCT with low proliferation activity, determined by Ki67 and argyrophilic nucleolar organising regions (AgNOR). Eighty-six dogs with cutaneous MCT were evaluated. All dogs had surgical excision of their MCT with a low Ki67 index and combined AgNORxKi67 (Ag67) values. Twenty-three (27%) dogs developed local or distant recurrence during the median follow-up time. Of these dogs, six (7%) had local recurrence, one had complete and five had incomplete histologic margins. This difference in recurrence rates between dogs with complete and incomplete histologic margins was not significant. On the basis of this study, ancillary therapy may not be necessary for patients with incompletely excised grade II MCT with low proliferation activity.
[Mh] Termos MeSH primário: Antígenos Nucleares/metabolismo
Doenças do Cão/metabolismo
Antígeno Ki-67/metabolismo
Mastocitose Cutânea/veterinária
Recidiva Local de Neoplasia/veterinária
[Mh] Termos MeSH secundário: Animais
Biomarcadores Tumorais/metabolismo
Doenças do Cão/epidemiologia
Doenças do Cão/cirurgia
Cães
Feminino
Estimativa de Kaplan-Meier
Masculino
Mastocitose Cutânea/epidemiologia
Mastocitose Cutânea/metabolismo
Mastocitose Cutânea/cirurgia
Recidiva Local de Neoplasia/epidemiologia
Recidiva Local de Neoplasia/metabolismo
Recidiva Local de Neoplasia/cirurgia
Estadiamento de Neoplasias/veterinária
Países Baixos/epidemiologia
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Nuclear); 0 (Biomarkers, Tumor); 0 (Ki-67 Antigen); 0 (nucleolar organizer region associated proteins)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150204
[St] Status:MEDLINE
[do] DOI:10.1111/vco.12140


  6 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27968936
[Au] Autor:Rothe MJ; Grant-Kels JM; Makkar HS
[Ad] Endereço:Department of Dermatology, University of Connecticut School of Medicine, Farmington, CT. Electronic address: rothe@uchc.edu.
[Ti] Título:Mast cell disorders: Kids are not just little people.
[So] Source:Clin Dermatol;34(6):760-766, 2016 Nov - Dec.
[Is] ISSN:1879-1131
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cutaneous mastocytosis is characterized by a pathologic increase in mast cells in the skin and may also involve extracutaneous organs. Symptoms, which are triggered by mast cell degranulation, vary depending on the burden of skin disease and the presence of extracutaneous disease. The clinical presentation, risk of systemic disease, pathogenesis, prognosis, and treatment options differ, largely depending on age at presentation. In the pediatric population, spontaneous remission is typical, generally by puberty, whereas in adults, progression is observed. Extracutaneous involvement and associated hematologic disorders seldom occur in children, as opposed to adults. It is therefore important to avoid overreliance on adult-based approaches to management of cutaneous mastocytosis in the pediatric population. We focus on differences in presentation, workup, and management of pediatric- and adult-onset cutaneous mast cell disorders.
[Mh] Termos MeSH primário: Mastocitose Cutânea/diagnóstico
Mastocitose Sistêmica/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Biópsia/métodos
Criança
Pré-Escolar
Seres Humanos
Lactente
Recém-Nascido
Mastocitose Cutânea/complicações
Mastocitose Cutânea/patologia
Mastocitose Cutânea/terapia
Prognóstico
Pele/patologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170620
[Lr] Data última revisão:
170620
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161215
[St] Status:MEDLINE


  7 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27846948
[Au] Autor:Seamens A; Taussig B; Penziner K; Smidt A; Lawley LP
[Ad] Endereço:Department of Dermatology, Emory University, Atlanta, Georgia.
[Ti] Título:Exploring the prevalence of learning disabilities in children with cutaneous mastocytosis: A pilot cohort study.
[So] Source:J Am Acad Dermatol;75(6):1254-1255, 2016 Dec.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Transtornos de Aprendizagem/epidemiologia
Mastocitose Cutânea/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Estudos de Coortes
Seres Humanos
Transtornos de Aprendizagem/diagnóstico
Projetos Piloto
Prevalência
Sensibilidade e Especificidade
Inquéritos e Questionários
[Pt] Tipo de publicação:LETTER
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161117
[St] Status:MEDLINE


  8 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27670724
[Au] Autor:Zaouri H; Amarouch H; Elmakrini N; Tazi N; Ismaili N; Benzekri L; Senouci K; Hassam B
[Ad] Endereço:Service de dermatologie, centre hospitalier universitaire Ibn Sina, rue Famfdal Cherkaoui, BP 6527, 10000 Rabat, Maroc. Electronic address: hasnaazaouri@yahoo.fr.
[Ti] Título:[Diffuse cutaneous mastocytosis of an infant: A case report].
[Ti] Título:Mastocytose cutanée diffuse du nourrisson : à propos d'un cas..
[So] Source:Arch Pediatr;23(11):1150-1152, 2016 Nov.
[Is] ISSN:1769-664X
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Mastocytosis is a group of diseases related to abnormal accumulation and proliferation of mast cells in one or more organs. They may be associated with an acquired point mutation and the activation of the receptor tyrosine-kinase c-KIT of CFS (mast cell growth factor). The clinical manifestations are varied and secondary to the release of mast cell mediators and/or infiltration of various organs. There are two main types of mastocytosis: pure cutaneous mastocytosis and systemic mastocytosis when more than two organs are involved in mast cell infiltration (bone marrow, gastrointestinal tract, bone, liver and spleen, lymph nodes). Mastocytosis affects children in two thirds of cases, most frequently as an isolated cutaneous form. The most common clinical form in children is urticaria pigmentosa and solitary mastocytoma; bullous diffuse mastocytosis is rare. We report the case of an 8-month-old infant who presented with a diffuse pruritic bullous eruption. The histology and immunohistochemistry results were suggestive of mastocytosis. A serum tryptase test yielded positive results. Laboratory investigations did not identify systemic involvement. The patient was given antihistamine H1 medication and local care. Advice regarding the disease was offered to the parents. The course of the disease was marked by a decrease in the number of blisters and attenuation of the pruritus at the 6-month follow-up. This observation emphasizes the importance of awareness of this rare entity, which should be considered in all cases of bullous dermatosis in children, thereby allowing for early treatment.
[Mh] Termos MeSH primário: Mastocitose Cutânea/patologia
[Mh] Termos MeSH secundário: Seres Humanos
Lactente
Masculino
Prurido/etiologia
Triptases/sangue
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.4.21.59 (Tryptases)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170418
[Lr] Data última revisão:
170418
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160928
[St] Status:MEDLINE


  9 / 280 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27650464
[Au] Autor:Macfarlane MJ; Macfarlane LL; Scase T; Parkin T; Morris JS
[Ad] Endereço:University of Glasgow, School of Veterinary Medicine, Glasgow, UK.
[Ti] Título:Use of neutrophil to lymphocyte ratio for predicting histopathological grade of canine mast cell tumours.
[So] Source:Vet Rec;179(19):491, 2016 Nov 12.
[Is] ISSN:2042-7670
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Canine mast cell tumours (MCTs) are variable in their biological behaviour and treatment decisions depend heavily on the histopathological grade. Biomarkers such as neutrophil to lymphocyte ratio (NLR) and albumin to globulin ratio are used to predict the biological behaviour of human neoplasms, but have not been widely studied in dogs. A retrospective analysis identified 62 cases of gross MCT (14 high-grade, 48 low-grade tumours). Median NLR was significantly different between high- and low-grade MCT and tumours at different locations. A multivariable model identified increasing NLR (OR 2.0) and age (OR 1.7) to be associated with an increased risk of high-grade MCT. Receiver operating characteristic curve analysis identified an NLR threshold value of 5.67 (sensitivity 85.7 per cent; specificity 54.2 per cent) for predicting a high-grade MCT. An NLR threshold of 5.67 could be useful alongside existing tools (appearance, location, etc.) to help to predict the grade of MCT. With further validation, this biomarker could be used to guide clinical decisions before obtaining a histopathological diagnosis.
[Mh] Termos MeSH primário: Doenças do Cão/patologia
Mastocitose Cutânea/patologia
Mastocitose Cutânea/veterinária
[Mh] Termos MeSH secundário: Animais
Biomarcadores Tumorais
Cães
Feminino
Contagem de Leucócitos
Contagem de Linfócitos
Masculino
Gradação de Tumores
Neutrófilos
Estudos Retrospectivos
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160922
[St] Status:MEDLINE
[do] DOI:10.1136/vr.103650


  10 / 280 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27545739
[Au] Autor:Abid A; Malone MA; Curci K
[Ad] Endereço:Department of Family and Community Medicine, Penn State Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA. Electronic address: aabid@hmc.psu.edu.
[Ti] Título:Mastocytosis.
[So] Source:Prim Care;43(3):505-18, 2016 Sep.
[Is] ISSN:1558-299X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mastocytosis is a rare disease caused by excessive production of mast cells. Clinical presentation is variable, often based on the type of mastocytosis, but in all types of mastocytosis there seems to be an increase in the risk of anaphylaxis. Systemic mastocytosis is diagnosed based on bone marrow biopsy. Treatment is variable based on the type of mastocytosis, but trigger avoidance and anaphylaxis treatment are mainstays. There are no therapies that change the natural course of mastocytosis. For cutaneous mastocytosis, treatment is conservative and aimed at symptom relief.
[Mh] Termos MeSH primário: Mastocitose Cutânea/fisiopatologia
Mastocitose Sistêmica/fisiopatologia
[Mh] Termos MeSH secundário: Anafilaxia/etiologia
Biópsia
Contagem de Células Sanguíneas
Análise Química do Sangue
Seres Humanos
Mastócitos/metabolismo
Mastocitose Cutânea/complicações
Mastocitose Cutânea/diagnóstico
Mastocitose Cutânea/terapia
Mastocitose Sistêmica/complicações
Mastocitose Sistêmica/diagnóstico
Mastocitose Sistêmica/terapia
Mutação
Atenção Primária à Saúde
Proteínas Proto-Oncogênicas c-kit/genética
Qualidade de Vida
Triptases/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
EC 2.7.10.1 (Proto-Oncogene Proteins c-kit); EC 3.4.21.59 (Tryptases)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170328
[Lr] Data última revisão:
170328
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160823
[St] Status:MEDLINE



página 1 de 28 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde